STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARQT
  4. [Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity

ARQT director Lin exercises options, updates holdings in Form 4

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Arcutis Biotherapeutics (ARQT) director Sue-Jean Lin reported stock option exercises and a share sale. On 11/24/2025, Lin exercised options to acquire 18,052 shares of common stock at an exercise price of $8.63 per share and another 7,220 shares at $7.51 per share. That same day, Lin sold 25,272 shares of common stock at a weighted average price of $30.7833 per share, in multiple trades between $30.56 and $30.91. After these transactions, Lin directly beneficially owned 26,735 shares of Arcutis common stock, along with remaining stock options for 9,000 shares and 5,000 shares that are exercisable into common stock.

Positive

  • None.

Negative

  • None.
Insider LIN SUE-JEAN
Role Director
Sold 25,272 shs ($778K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 18,052 $0.00 --
Exercise Stock Option (right to buy) 7,220 $0.00 --
Exercise Common Stock 18,052 $8.63 $156K
Exercise Common Stock 7,220 $7.51 $54K
Sale Common Stock 25,272 $30.7833 $778K
Holdings After Transaction: Stock Option (right to buy) — 9,000 shares (Direct); Common Stock — 44,787 shares (Direct)
Footnotes (1)
  1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LIN SUE-JEAN
(Last) (First) (Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300
(Street)
WESTLAKE VILLAGE CA 91361
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/24/2025 M(1) 18,052 A $8.63 44,787 D
Common Stock 11/24/2025 M(2) 7,220 A $7.51 52,007 D
Common Stock 11/24/2025 S(3) 25,272 D $30.7833(3) 26,735 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $8.63 11/24/2025 M(1) 18,052 (1) 06/14/2034 Common Stock 18,052 $0 9,000 D
Stock Option (right to buy) $7.51 11/24/2025 M(2) 7,220 (2) 05/31/2033 Common Stock 7,220 $0 5,000 D
Explanation of Responses:
1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
2. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
3. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks:
/s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Arcutis Biotherapeutics (ARQT) director Sue-Jean Lin report on this Form 4?

The filing reports that Sue-Jean Lin, a director of Arcutis Biotherapeutics (ARQT), exercised stock options to acquire shares of common stock and sold a portion of those shares on 11/24/2025. It also updates her remaining share and option holdings after these transactions.

How many Arcutis (ARQT) shares did Sue-Jean Lin acquire through option exercises?

On 11/24/2025, Sue-Jean Lin exercised stock options to acquire 18,052 shares of Arcutis common stock at an exercise price of $8.63 per share, and separately 7,220 shares at an exercise price of $7.51 per share.

How many Arcutis (ARQT) shares did Sue-Jean Lin sell, and at what price?

On 11/24/2025, Sue-Jean Lin sold 25,272 shares of Arcutis common stock at a weighted average price of $30.7833 per share. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive.

How many Arcutis (ARQT) shares does Sue-Jean Lin own after these transactions?

Following the reported transactions, Sue-Jean Lin directly beneficially owned 26,735 shares of Arcutis Biotherapeutics common stock.

What stock options does Sue-Jean Lin still hold in Arcutis (ARQT)?

After the exercises on 11/24/2025, Sue-Jean Lin held stock options for 9,000 shares of Arcutis common stock with an exercise price of $8.63 per share and options for 5,000 shares with an exercise price of $7.51 per share.

How do the vesting terms work for the reported Arcutis (ARQT) stock options?

One option grant vests and becomes exercisable as to 100% of its shares on the first anniversary of June 14, 2024, and another vests as to 100% of its shares on the first anniversary of May 31, 2023, in each case subject to the non-employee director’s continuous service.